Literature DB >> 10454753

P-glycoprotein-mediated resistance to chemotherapy in cancer cells: using recombinant cytosolic domains to establish structure-function relationships.

A Di Pietro1, G Dayan, G Conseil, E Steinfels, T Krell, D Trompier, H Baubichon-Cortay, J Jault.   

Abstract

Resistance to chemotherapy in cancer cells is mainly mediated by overexpression of P-glycoprotein (Pgp), a plasma membrane ATP-binding cassette (ABC) transporter which extrudes cytotoxic drugs at the expense of ATP hydrolysis. Pgp consists of two homologous halves each containing a transmembrane domain and a cytosolic nucleotide-binding domain (NBD) which contains two consensus Walker motifs, A and B, involved in ATP binding and hydrolysis. The protein also contains an S signature characteristic of ABC transporters. The molecular mechanism of Pgp-mediated drug transport is not known. Since the transporter has an extraordinarily broad substrate specificity, its cellular function has been described as a "hydrophobic vacuum cleaner". The limited knowledge about the mechanism of Pgp, partly due to the lack of a high-resolution structure, is well reflected in the failure to efficiently inhibit its activity in cancer cells and thus to reverse multidrug resistance (MDR). In contrast to the difficulties encountered when studying the full-length Pgp, the recombinant NBDs can be obtained in large amounts as soluble proteins. The biochemical and biophysical characterization of recombinant NBDs is shown here to provide a suitable alternative route to establish structure-function relationships. NBDs were shown to bind ATP and analogues as well as potent modulators of MDR, such as hydrophobic steroids, at a region close to the ATP site. Interestingly, flavonoids also bind to NBDs with high affinity. Their binding site partly overlaps both the ATP-binding site and the steroid-interacting region. Therefore flavonoids constitute a new promising class of bifunctional modulators of Pgp.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10454753     DOI: 10.1590/s0100-879x1999000800001

Source DB:  PubMed          Journal:  Braz J Med Biol Res        ISSN: 0100-879X            Impact factor:   2.590


  12 in total

1.  Combination of suboptimal doses of inhibitors targeting different domains of LtrMDR1 efficiently overcomes resistance of Leishmania spp. to Miltefosine by inhibiting drug efflux.

Authors:  José M Pérez-Victoria; Fernando Cortés-Selva; Adriana Parodi-Talice; Boris I Bavchvarov; F Javier Pérez-Victoria; Francisco Muñoz-Martínez; Mathias Maitrejean; M Paola Costi; Denis Barron; Attilio Di Pietro; Santiago Castanys; Francisco Gamarro
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

2.  [Role of protein kinase D1 in regulating the growth, apoptosis and drug sensitivity of oral squamous carcinoma cells].

Authors:  Jing-Nan Wang; Ya-Ping Fan; Jiao Chen; Yun Feng; Bo-Miao Cui; Xiao-Ying Li; Li-Wei Wang; Hong-Li Chen; Ping Zhang; Hong-Kun Wu
Journal:  Hua Xi Kou Qiang Yi Xue Za Zhi       Date:  2019-12-01

3.  High-affinity binding of silybin derivatives to the nucleotide-binding domain of a Leishmania tropica P-glycoprotein-like transporter and chemosensitization of a multidrug-resistant parasite to daunomycin.

Authors:  J M Pérez-Victoria; F J Pérez-Victoria; G Conseil; M Maitrejean; G Comte; D Barron; A Di Pietro; S Castanys; F Gamarro
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

4.  Cancer-relevant biochemical targets of cytotoxic Lonchocarpus flavonoids: a molecular docking analysis.

Authors:  Caitlin E Cassidy; William N Setzer
Journal:  J Mol Model       Date:  2009-07-15       Impact factor: 1.810

5.  A plausible explanation for enhanced bioavailability of P-gp substrates in presence of piperine: simulation for next generation of P-gp inhibitors.

Authors:  Durg Vijay Singh; Madan M Godbole; Krishna Misra
Journal:  J Mol Model       Date:  2012-08-04       Impact factor: 1.810

6.  ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal.

Authors:  Cheol-Hee Choi
Journal:  Cancer Cell Int       Date:  2005-10-04       Impact factor: 5.722

7.  Combination of tunicamycin with anticancer drugs synergistically enhances their toxicity in multidrug-resistant human ovarian cystadenocarcinoma cells.

Authors:  Donavon C Hiss; Gary A Gabriels; Peter I Folb
Journal:  Cancer Cell Int       Date:  2007-04-18       Impact factor: 5.722

Review 8.  Antitumor Drugs and Their Targets.

Authors:  Zlatko Dembic
Journal:  Molecules       Date:  2020-12-07       Impact factor: 4.411

Review 9.  Natural product-based nanomedicine: recent advances and issues.

Authors:  Rebekah Watkins; Ling Wu; Chenming Zhang; Richey M Davis; Bin Xu
Journal:  Int J Nanomedicine       Date:  2015-09-28

Review 10.  Salmonella-Based Targeted Cancer Therapy: Updates on A Promising and Innovative Tumor Immunotherapeutic Strategy.

Authors:  Christian Ronquillo Pangilinan; Che-Hsin Lee
Journal:  Biomedicines       Date:  2019-05-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.